Search
/ For experts / Clinical trials

Are you a healthcare professional?

I am a specialist within the meaning of Act No. 40/1995 Coll., on the Regulation of Advertising, as amended, i.e. I am a person authorised to prescribe medicinal products for human use or a person authorised to dispense medicinal products for human use.





YES, enter NO, leave

Clinical trials

STUDIES WITH ACTIVE RECRUITMENT

PRSU FINDINGS

Randomized phase III trial evaluating the efficacy and safety of camizextran (AZD9833-oral SERD) versus standard hormonal therapy (aromatase inhibitor or tamoxifen), possibly in combination with abemaciclib, as adjuvant therapy in patients with hormone-dependent and HER-negative early breast cancer at intermediate and high risk of recurrence who have undergone complete locoregional therapy and are in complete remission.

CAMBRIA 2
Diagnosis: C50.0-C50.9
Start date: May 2024
Principal investigator: prof. MUDr. Karel Odrážka, Ph.D.
The study is ongoing, recruitment active
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz, linkova@multiscan.cz)

MALE GENITAL TUMOURS

Randomized, double-blind, placebo-controlled phase 3 trial comparing per os MEVROMETOSTAT (PF-06821497) with enzalutamide versus enzalutamide with placebo in untreated patients with metastatic castration-resistant (mCRPC)

Title: MEVPRO-2
Diagnosis: C61
Start date: June 2025
Principal Investigator: prof. MUDr. Karel Odrážka, Ph.D.
Study ongoing, recruitment active
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz, linkova@multiscan.cz)

Randomized, open-label, phase 3 trial comparing per os MEVROMETOSTAT (PF-06821497) in combination with enzalutamide versus enzalutamide or docetaxel in patients with mCRPC previously treated with abiraterone acetate

Title: MEVPRO-1
Diagnosis: C61
Start date: June 2025
Principal Investigator: prof. MUDr. Karel Odrážka, Ph.D.
Study ongoing, recruitment active
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz, linkova@multiscan.cz)

PLIC FINDINGS

Randomized phase III trial investigating the effect of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab maintenance therapy with or without IP MK-2870 in the first-line treatment of metastatic non-small cell lung cancer.

Name: MK-2870-023
Diagnosis: C34.9
Start date: March 2025
Principal Investigator: prof. MUDr. Karel Odrážka, Ph.D.
Study ongoing, recruitment active
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan, linkova@multiscan.cz)

Randomized, unblinded phase 3 study evaluating the efficacy of MK-2870 conjugated antibody in combination with pembrolizumab versus pembrolizumab monotherapy in first-line treatment of patients with metastatic non-small cell lung cancer with PD-L1 expression of 50 percent or more.

Diagnosis: C34.9
Start date: June 2024
Principal Investigator: prof. MUDr. Karel Odrážka, Ph.D.
Study ongoing, recruitment active
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan, linkova@multiscan.cz)

STUDIES WITH COMPLETED RECRUITMENT

PRSU FINDINGS

Phase 3 adjuvant trial of imlunestrate vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) at increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET.

Name: EMBER-4 (J2J-MC-JZLH)
Diagnoses: C50.0-C50.9
Start date: May 4, 2023
Principal Investigator: prof. MUDr. Karel Odrážka, Ph.D.
The study is ongoing, recruitment completed
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz, linkova@multiscan.cz)

Phase III adjuvant study evaluating the effect of camizepantrant (AZD9833- oral SERD) versus standard endocrine therapy (aromatase inhibitor or tamoxifen) in patients with ER+, HER2- early breast cancer (EBC) at increased risk of recurrence who have previously received 2 to 5 years of adjuvant hormonal therapy.

Name: AZ Cambria-1
Diagnosis: C50.0-C50.9
Start date: 10/30/2023
Principal Investigator: prof. MUDr. Karel Odrážka, Ph.D.
The study is ongoing, recruitment completed
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz, linkova@multiscan.cz)

Randomized phase III trial assessing sacituzumab-govitecan versus chemotherapy (capecitabine or paclitaxel) in patients with hormone receptor-dependent and HER-negative (IHC 0 or HER2 low) breast cancer that is inoperable, locally advanced or metastatic. Patients must have exhausted palliative hormone therapy options, including the use of CDK 4/6 inhibitors.

ASCENT - 07
Diagnosis: C50.0-C50.9
Start date: January 2024
Principal investigator: prof. MUDr. Karel Odrážka, Ph.D.
The study is ongoing, recruitment completed
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz, linkova@multiscan.cz)

Randomized, double-blind, placebo-controlled phase III trial comparing the efficacy of abemaciclib+ fulvestrant versus placebo with fulvestrant in women (or men) with HR+ and HER- breast cancer who have either 1/progression on treatment 1. line with CDK4/4 inhibitor + aromatase inhibitor in advanced disease or 2/ progress on CDK4/6 inhibitor + hormone therapy in adjuvant indication.

Name: postMONARCH I3Y-MC-JPEF
Start date: 2022
Principal Investigator: prof. MUDr. Karel Odrážka, Ph.D.
Study ongoing, recruitment completed
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz, linkova@multiscan.cz)

Randomized, multicenter, double-blind phase III study comparing SAR439859 in combination with palbociclib versus letrozole with palbociclib for the treatment of patients with estrogen receptor positive (ER+) and HER2 negative breast cancer who have received no prior systemic anti-cancer therapy for advanced disease.

Diagnoses: C50.0-C50.9
Start date: April 8, 2021
Principal investigator: prof. MUDr. Karel Odrážka, Ph.D.
The study is ongoing, recruitment completed
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz, linkova@multiscan.cz)

Randomized, open-label, phase 3 clinical trial of abemaciclib in combination with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with early stage HR positive, HER2 negative breast cancer with nodal involvement and high risk of recurrence. MONARCHE

Diagnoses: C50.0-C50.9
Start date: 12/15/2017
Principal Investigator: doc. MUDr. Jaroslav Vaňásek, CSc.
The study is ongoing, recruitment is completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized, multicenter, double-blind, placebo-controlled trial comparing chemotherapy with trastuzumab and placebo versus chemotherapy with trastuzumab and pertuzumab as supportive care in patients with operable HER2-positive primary breast cancer. APHINITY BO 25126

Diagnoses: C50.0-C50.9
Start date: 05/11/2012
Principal Investigator: doc. MUDr. Jaroslav Vaňásek, CSc.
The study is ongoing, recruitment is completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized, double-blind, controlled phase 2 study of tukatinib vs. placebo in combination with capecitabine and trastuzumab in patients with already treated unresectable locally advanced or metastatic HER2-positive breast cancer.

Diagnoses: C50.0-C50.9
Start date: 12/18/2017
Principal Investigator: doc. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásek, M.D., Professor of Medicine, Czech Republic
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

An open-label, multicenter phase IIIb clinical trial evaluating the safety and efficacy of ribociclib (LEE011) in combination with letrozole in the treatment of male, premenopausal and postmenopausal women with hormone-receptor positive (HR+), HER2-negative (HER2-), advanced breast cancer without prior hormone therapy for advanced disease.

Diagnoses: C50.0-C50.9
Start date: Aug 25, 2017.
Chief Examiner: doc. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásek, Ph.D., professor of medicine, Dr. Jaroslav Vaňásek, professor of medicine
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

A double-blind, placebo-controlled, randomized phase III clinical trial evaluating taselisib in combination with fulvestrant versus placebo in combination with fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative estrogen receptor-positive breast cancer who experienced recurrence or progression of disease during or after aromatase inhibitor treatment.

Diagnoses: C50.0-C50.9
Start date: 22 June 2015
Chief Investigator: doc. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásek, M.D., Professor of Medicine, Ph.D. The study has been completed.
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Multi-stage phase II study evaluating the safety and efficacy of cobimetinib in combination with paclitaxel as a first-line treatment in patients with metastatic triple-negative breast cancer.

Diagnoses: C50.0-C50.9
Start date: April 1, 2015
Principal Investigator: doc. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásek, M.D., Professor of Medicine, Czech Republic
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized, double-blind, phase II clinical trial of neoadjuvant treatment with the combination of letrozole and GDC-0032 compared to letrozole and placebo in postmenopausal women with early stage ER positive/HER 2 negative breast cancer.

Diagnoses: C50.0-C50.9
Start date: December 15, 2014
Principal Investigator. MUDr. Jaroslav Vaňásek,CSc.
Jaroslav Vaňásek, M.D., Ph.D. The study is completed.
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized, multicenter, open-label, phase III clinical trial comparing trastuzumab with pertuzumab and taxane after anthracycline treatment and trastuzumab emtasim with pertuzumab after anthracycline treatment as adjunctive therapy in patients with operable HER2-positive primary breast cancer.

Diagnoses: C50.0-C50.9
Start date: April 30, 2014
Principal Investigator: Iveta Kolářová, M.D., Ph.D.
Iveta Kolářová, Iveta Kolářová, PhD, PhD
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

A study evaluating the use of neratinib and capecitabine compared to lapatinib and capecitabine in patients with HER2+ metastatic breast cancer who have undergone two or more prior HER2-targeted metastatic regimens (Nala).

Diagnoses: C50.0-C50.9
Start date: November 6, 2013.
Principal Investigator. MUDr. Jaroslav Vaňásek,CSc.
The study is completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

MALE GENITAL TUMOURS

A double-blind, randomized, placebo-controlled phase III study evaluating the efficacy and safety of Capivasertib + docetaxel versus placebo + docetaxel as a treatment for patients with metastatic castration-resistant prostate cancer (mCRPC)

Name: Capitello 280 (D361EC0001)
Diagnosis: C61
Start date: 12/9/2022
Principal investigator: prof. MUDr. Karel Odrážka, Ph.D.
Study ongoing, recruitment completed
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz, linkova@multiscan.cz)

Randomized, double-blind, placebo-controlled phase 3 study evaluating Talazoparib with Enzalutamide in metastatic castration-resistant prostate cancer. TALAPRO-2

Diagnosis: C61
Start date: Sep 19, 2019
Principal Investigator. MUDr. Jaroslav Vaňásek, CSc.
The study is ongoing, recruitment is completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized, double-blind, placebo-controlled phase 3 clinical trial of the combination of niraparib with abiraterone acetate and prednisone versus abiraterone acetate with prednisone in the treatment of metastatic prostate cancer. PCR 3001

Diagnosis: C61
Start date: 4/16/2019
Principal Investigator. MUDr. Jaroslav Vaňásek, CSc.
The study is ongoing, recruitment is complete
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized, double-blind, placebo-controlled phase III clinical trial of JNJ-56021927 in men with high-risk localized or locally advanced prostate cancer undergoing primary radiotherapy. PCR 3003

Diagnosis: C61
Start date: 2016
Principal investigator: prof. MUDr. Karel Odrážka, Ph.D.
The study is ongoing, recruitment completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Multicentre, randomised, assessor-blinded, controlled clinical trial comparing the incidence of major adverse cardiovascular events (MACE) in patients with prostate cancer and cardiovascular disease taking degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).

Diagnosis: C61
Start date: June 4, 2018
Principal Investigator: doc. MUDr. Jaroslav Vaňásek, CSc.
The study is completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized, double-blind, placebo-controlled phase III clinical trial comparing JNJ562 androgen deprivation therapy (ADT) versus androgen deprivation therapy alone in subjects with metastatic hormone-sensitive prostate cancer (mHSPC) with a small number of "low volume" metastases. Low volume: bone metastases minimum 2, if 2 or 3 possibly anywhere, if 4 or more must all be in the pelvis and spine: no nodal metastases only, no visceral metastases.

Diagnosis: C61
Start date: 2016
Principal investigator: prof. MUDr. Karel Odrážka, Ph.D.
Karel Odrazka, Karel Odrazka, MD, PhD, professor of medicine
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized double-blind placebo-controlled phase I/II study of the effect of RNActive-based tumor vaccine (CV9104) in patients with metastatic castration-resistant prostate cancer presenting minimal or no symptoms.

Start date: December 4, 2015
Principal Investigator: prof. MUDr. Karel Odrážka, Ph.D.
Study completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

PLIC FINDINGS

Multicenter, double-blind, randomized, controlled clinical trial of M7824 with concurrent chemoradiotherapy followed by M7824 versus concurrent chemoradiotherapy plus placebo followed by durvalumab in participants with unresectable stage III non-small cell lung cancer.

Diagnoses: C34.0-C34.9
Start date: 21 January 2021
Principal investigator: prof. MUDr. Karel Odrážka, Ph.D.
The study is ongoing, recruitment completed
Coordinators: Bc. Barbora Chocholoušová, Mgr. Sandra Línková (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz, linkova@multiscan.cz)

Multicentre, double-blind, randomised, controlled clinical trial of M7824 with concurrent chemoradiotherapy followed by M7824 versus concurrent chemoradiotherapy plus placebo followed by durvalumab in participants with unresectable stage III non-small cell lung cancer.

Diagnoses: C34.0 - C34.9
Start date: 29 October 2020
Chief Investigator: prof. MUDr. Karel Odrážka, PhD.
The study is ongoing, recruitment completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

An international, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of BSD-100 in combination with pemetrexed+ cisplatin/carboplatin compared to placebo in combination with pemetrexed+ cisplatin/carboplatin as first-line treatment in patients with advanced/metastatic non-small cell lung cancer.

Diagnoses: C34.0 - C34.9
Start date: June 2020
Principal Investigator: Mojmír Randula, MD
Study ongoing, recruitment complete
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

An open-label, multicentre, randomised phase III clinical trial to determine the safety and efficacy of an EGF vaccine in patients with inoperable stage IV NSCLC with positive wild-type EGFR biomarkers who meet the criteria for standard treatment and supportive care.

Diagnoses: C34.0 - C34.9
Start date: Jan 3, 2018
Principal Investigator. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásek, MD, PhD.
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Phase I dose escalation and randomized, double-blind phase II clinical trial of veliparib in combination with CBDCA and etoposide in the treatment of untreated extensive stage small cell lung cancer.

Diagnoses: C34.0 - C34.9
Start date: March 2017
Principal Investigator: doc. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásák, MD, PhD.
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized, open-label, multicenter phase II clinical trial comparing veliparide with carboplatin and paclitaxel versus standard investigator's choice chemotherapy in patients treated with first-line cytotoxic chemotherapy for metastatic or advanced non-squamous non-small cell lung cancer (NSCLC) who are or were smokers.

Diagnoses: C34.0 - C34.9
Start date: June 26, 2015
Principal Investigator. MUDr. Jaroslav Vaňásek, CSc.
Studie ukončena
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Unblinded randomized phase III clinical trial comparing treatment with MK 3475 versus standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer (Keynote 42).

Diagnoses: C34.0 - C34.9
Start date: January 13, 2015
Principal Investigator: doc. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásek, MD, PhD.
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Phase I/II study evaluating the safety and efficacy of DCVAC/LuCA added to standard chemotherapy (carboplatin and paclitaxel) in first-line +/- immunomodulators (interferon-alpha and hydrochloroquine) vs. standard chemotherapy in patients with stage IV non-small cell lung cancer.

Diagnoses: C34.0 - C34.9.
Start date: 12 January 2015
Chief Examiner: doc. MUDr. Jaroslav Vaňásek, CSc.
The study has been completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Phase III clinical trial of MPDL3280A with cisplatin or carboplatin and pemetrexed in PD-L1 selective patients with stage IV non-small cell lung cancer not yet treated with chemotherapy.

Diagnoses: C34.0 - C34.9
Start date: 2015
Principal Investigator. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásák, MD, Ph.D., Professor of Medicine, completed the study
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Phase III clinical trial of MPDL3280A with cisplatin or carboplatin and pemetrexed in PD-L1 selective patients with stage IV non-small cell lung cancer not yet treated with chemotherapy.

Diagnoses: C34.0 - C34.9
Start date: 2015
Principal Investigator. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásák, MD, Ph.D., Professor of Medicine, Dr. Vaňásák, Ph.D. The study is completed.
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Phase III clinical trial of avelumab (MSB0010718C) versus docetaxel in NSCLC that progressed after treatment with platinum-based doublet.

Diagnoses: C34.0 - C34.9
Start date: 2015
Principal Investigator. MUDr. Jaroslav Vaňásek,CSc.
The study is completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized, double-blind, multicenter, phase II clinical trial of denosumab in combination with chemotherapy as first-line treatment for metastatic non-small cell lung cancer.

Diagnoses: C34.0 - C34.9
Start date: 9 April 2014
Principal Investigator: doc. MUDr. Jaroslav Vaňásek,CSc.
The study has been completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

BLADDER TUMOURS

An unblinded randomised phase III clinical trial investigating the efficacy and safety of MPDL3280A (anti-Ligand PD-L1 antibody) compared to chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after failed platinum-containing chemotherapy.

Diagnoses: C67.0 - C67.9
Start date: March 30, 2015
Chief Examiner: doc. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásek, MD, Ph.D., Professor of Medicine, Dr. Jan Vaňásek, Ph.D. The study is completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Phase III clinical trial evaluating MPDL3280A as an adjunctive therapy in patients with high-risk PD-L1-expressing bladder cancer infiltrating the muscle who have undergone cystectomy.

Diagnoses: C67.0 - C67.9
Start date: 2015
Principal Investigator. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásek, M.D., Ph.D., Professor of Medicine, Dr. Vaňásek
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

TUMOURS OF THE DIGESTIVE TRACT AND DIGESTIVE ORGANS

Double-blind placebo-controlled phase II study evaluating dasatinib added to gemcitabine in patients with locally advanced pancreatic cancer.

Diagnoses: C250-C259
Start date: November 15, 2011
Principal Investigator: doc. Jaroslav Vaňásek, MUDr., CSc.
The study is completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Randomized, double-blind, multicenter phase III clinical trial of irinotecan, folinic acid and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal cancer progressing during or after first-line treatment with the combination of bevacizumab, oxaliplatin and fluoropyrimidine.

Diagnoses: C18-C20
Start date: 6 May 2011
Principal investigator: doc. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásek, MD, PhD, Professor of Medicine, completed the study.
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Open-label, randomized, controlled, multicenter, phase I/II clinical trial evaluating two doses of EMD 525797 in combination with cetuximab and irinotecan as second-line treatment in patients with metastatic colorectal cancer with wild-type k-ras gene. Patients with metastatic colorectal cancer with the wild-type k-ras gene will be eligible for enrolment in the clinical trial if their disease is refractory to or recurs after first-line chemotherapy with a regimen including oxaliplatin.

Diagnoses: C18-C20
Start date: 12 May 2010
Principal Investigator: doc. MUDr. Jaroslav Vaňásek, CSc.
Jaroslav Vaňásek, M.D., Professor of Medicine, Ph.D. The study has been completed.
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

CENTRAL NERVOUS SYSTEM TUMOURS

International, randomized, double-blind, controlled trial of rindopepimut/GM-CSF with adjuvant temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII positive glioblastoma.

Diagnoses: C71.0 - C71.9
Start date: 18 October 2012
Chief Investigator: prof. MUDr. Karel Odrážka, Ph.D.
Study completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

NOT RESTRICTED

Efficacy and safety of Rivaroxaban prophylaxis compared to placebo in outpatient cancer patients starting systemic anticancer therapy who are at high risk of venous thromboembolism.

Start date: March 2017
Principal Investigator. MUDr. Jaroslav Vaňásek, CSc.
M.Vaňásek, M.D., Ph.D. The study is completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)

Multicentre, randomised, double-blind, active-controlled phase III study investigating the safety and efficacy of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy.

Start date: 18 July 2012
Principal Investigator. MUDr. Jaroslav Vaňásek, CSc.
The study has been completed
Coordinators: Bc. Barbora Chocholoušová (tel.: 466 686 518, e-mail: chocholousova@multiscan.cz)